Skip to main content

Table 2 Baseline characteristics of participants

From: Double blind randomized placebo-controlled trial on the effects of testosterone supplementation in elderly men with moderate to low testosterone levels: design and baseline characteristics [ISRCTN23688581]

  Testosterone (n = 120) Placebo (n = 117)
Age (yr) 67.3 ± 5.1 67.5 ± 5.0
Weight (Kg) 86.1 ± 13.3 84.4 ± 13.6
Body Mass Index (kg/m2) 27.54 ± 3.85 27.20 ± 3.90
Smokers 21 (17.5) 15 (12.8)
Alcohol users 99 (82.5) 85 (77.3)
Hypertension 75 (62.5) 69 (59)
Systolic Blood Pressure (mm/Hg) 156.2 ± 23.2 151.1 ± 22.6
Diastolic Blood Pressure (mm/Hg) 89.8 ± 12.0 86.8 ± 11.7
Pulse Pressure (mm/Hg) 66.4 ± 15.9 64.3 ± 15.2
Pulse Wave Velocity (m/s) 10.00 ± 2.51 9.53 ± 2.66
Total Testosterone (nmol/L) 10.93 ± 2.06 10.50 ± 1.89
Free Testosterone (nmol/L) 0.22 ± 0.05 0.21 ± 0.05
Bioavailable Testosterone (nmol/L) 5.23 ± 1.15 5.04 ± 1.20
SHBG (nmol/L) 33.17 ± 10.59 32.90 ± 10.38
Albumin (g/L) 43.94 ± 2.31 43.80 ± 2.38
Cholestrol (mmol/L) 5.61 ± 0.99 5.50 ± 0.97
HDL (mmol/L) 1.16 ± 0.28 1.16 ± 0.29
LDL (mmol/L) 3.92 ± 0.91 3.80 ± 0.87
Insuline (mIU/L) 10.14 ± 9.50 8.73 ± 5.41
C-reactive proteine (mg/L) 4.27 ± 6.56 4.09 ± 6.97
PSA (μg/L) 1.54 ± 1.1 1.63 ± 1.1
Creatinine (μmol/L) 93.35 ± 18.0 93.72 ± 15.2
ASAT (U/L) 22.98 ± 8.1 24.21 ± 12.2
ALAT (U/L) 26.36 ± 11.0 26.74 ± 13.6
AF (U/L) 71.57 ± 19.2 69.91 ± 17.9
GGT (U/L) 29.51 ± 15.751 30.18 ± 19.9
Hemoglobine (mmol/L) 9.18 ± 0.5 9.14 ± 0.6
Hematocrit (%) 0.45 ± 0.0 0.45 ± 0.0
Prostate Volume (ultra sound) (cc) 28.20 ± 12.4 27.6 ± 9.8
IPSS 6.38 ± 5 6.50 ± 4.8
  1. Values are means or numbers with S.D. or percentage in parentheses.